On March 19, 2024, Avidity Biosciences, Inc. closed the transaction. The transaction included participation from 45 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.1 USD | +3.99% | +5.94% | +199.45% |
05-08 | Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 | MT |
05-08 | Avidity's Lead Program Gets FDA Breakthrough Designation | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+199.45% | 2.49B | |
-3.35% | 88.91B | |
+2.76% | 41.25B | |
-13.92% | 31.99B | |
+50.51% | 24.73B | |
-15.25% | 15.54B | |
-39.93% | 12.07B | |
-9.08% | 12.05B | |
-14.80% | 12.02B | |
+6.22% | 8.84B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding